# Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention

Study · id `cardio:ct-nct02498431` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02498431](<https://clinicaltrials.gov/study/NCT02498431>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02498431

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 116 participants.

## Technical summary

Registry record NCT02498431. Non-randomized; no masking; primary purpose diagnostic. Start 2015-06 (registry gives no type); primary completion 2015-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase: Not applicable
- Enrolled: 116 participants (enrolled count; ClinicalTrials.gov record NCT02498431, source copy `cardio:ctgov-nct02498431-2017-01-18`, retrieved 2026-10-26)
- Start date: 2015-06 (registry gives no type) (ClinicalTrials.gov record NCT02498431, source copy `cardio:ctgov-nct02498431-2017-01-18`, retrieved 2026-10-26)
- Primary completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02498431, source copy `cardio:ctgov-nct02498431-2017-01-18`, retrieved 2026-10-26)
- Completion: 2015-12 (actual) (ClinicalTrials.gov record NCT02498431, source copy `cardio:ctgov-nct02498431-2017-01-18`, retrieved 2026-10-26)
- Countries: Greece (ClinicalTrials.gov record NCT02498431, source copy `cardio:ctgov-nct02498431-2017-01-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02498431-2017-01-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention
- Acronym: IRICARDIO
- Condition: Myocardial Infarction
- Condition: Coronary Artery Disease
- Intervention (Procedure): percutaneous coronary intervention
- Intervention (Procedure): coronary angiography
- Intervention (Device): Stent, Medronic Resolute Integrity
- Lead sponsor: 424 General Military Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)

## Provenance

Content hash: 74e865460b4becd3a9d0a3f0089d090ed8d34d66ab661651d6741710f01ae95a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
